Mon, February 17, 2025
Sun, February 16, 2025
Sat, February 15, 2025
Fri, February 14, 2025
Thu, February 13, 2025

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2024 Earnings Call Transcript

  Copy link into your clipboard //science-technology.news-articles.net/content/2 .. asdaq-pacb-q4-2024-earnings-call-transcript.html
  Print publication without navigation Published in Science and Technology on by MSN
          🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source
Q4 2024 Earnings Call Transcript February 13, 2025 Pacific Biosciences of California, Inc. beats earnings expectations. Reported EPS is $0.51, expectations were $-0.2. Operator: Good day. And welcome to the PacBio Fourth Quarter 2024 Earnings Conference Call.
The article provides a transcript of the Q4 2024 earnings call for Pacific Biosciences of California, Inc. (NASDAQ: PACB). During the call, the company discussed its financial performance for the fourth quarter, highlighting a significant increase in revenue driven by strong demand for their sequencing products. Key points included updates on their product development, particularly the Revio sequencing system, which has been well-received in the market. The management also touched on strategic partnerships, advancements in technology, and their outlook for 2025, expressing optimism about future growth and market expansion. They also addressed operational challenges, including supply chain issues, and provided insights into their ongoing research and development efforts aimed at enhancing their technology's capabilities and reducing costs.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/technology/biotechnology/pacific-biosciences-of-california-inc-nasdaq-pacb-q4-2024-earnings-call-transcript/ar-AA1z6IXX ]